All In Biotech

Drug Trial Radar · NCT05604261

A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis

A Multicenter, Randomized, Double-blind, Double-dummy, Positive Drug Parallel Controlled Phase II Clinical Trial to Evaluate Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis

Last checked: Nov 19, 2026Latest source record: Nov 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

156

Planned (sponsor's estimate)

Start

Dec 2022

Primary completion

Jul 2023

Study completion Mar 2024

Sponsor

Sponsor type
Industry
First posted
Nov 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 2, randomized, double-blind, double-dummy, positive drug parallel controlled, multicenter trial to evaluate efficacy and safety of within 8 weeks (including 8 weeks) treatment of Anaprazole 40mg QD, 60mg QD compared with Rabeprazole 20mg QD in patients with reflux esophagitis.

Conditions

  • Reflux Esophagitis
  • Gastroesophageal Reflux
  • Esophagitis
  • Esophageal Motility Disorders
  • Deglutition Disorders
  • Esophageal Diseases
  • Gastrointestinal Diseases

Interventions

  • Anaprazole sodium 40 mgDrug

    Anaprazole sodium 2 tablets (20 mg/tablet) + Anaprazole sodium dummy tablets 1 tablet (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).

  • Anaprazole sodium 60 mgDrug

    Anaprazole sodium 3 tablets (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).

  • Rabeprazole sodium 20 mgDrug

    Anaprazole sodium dummy tablets 3 tablets (20 mg/tablet) + Rabeprazole sodium 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The endoscopic healing rate of reflux esophagitis within 8 weeks (including 8 weeks)Time frame: Treatment of 4 weeks or 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Changhai Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.